Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
cancer
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
7
×
texas top stories
wisconsin blog main
wisconsin top stories
deals
pfizer
startups
alzheimer's disease
biogen
eli lilly
ipo
medicare
merck
alexion pharmaceuticals
amgen
What
bio
roundup
7
×
drug
new
companies
gene
life
millions
moves
patients
pharmaceutical
plan
price
science
talk
typically
acquisitions
activity
advantages
alzheimer’s
approval
approvals
bails
bar
becker
biggest
billions
biogen
biogen’s
biopharmaceutical
brand
bridgebio
brings
build
buy
capital
car
ceo
clamped
company’s
Language
unset
Current search:
roundup
×
novartis
×
" boston top stories "
×
cancer
×
" texas blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More